Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.

Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting ...

Discover how leveraging TLR7/8 agonists in combination with systemic IFN-I represents a promising strategy for treating melanoma.

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

To assess whether NK cells were involved in antitumor response generated by fasting, Delconte and her team depleted these ...